Semi-annual Performance Forecast for 2026
Filed with SSE · · 3 pages · Chinese
Summary by 6ix AI
The company anticipates a net profit attributable to shareholders in the range of negative values, reflecting a significant decline compared to the previous year. The company is implementing strategies to enhance market presence and product offerings despite these difficulties.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
On 6ix: 6ix.com/news/zhejiang-east-asia-pharmaceutical-co-ltdsemi-annual-performance-forecast-for-2026
Zhejiang East Asia Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang East Asia Pharmaceutical
- Announcement on Not Revising Downward the Conversion Price of "East-Asia Convertible Bonds"
- Indicative Announcement on "East-Asia Convertible Bonds" Expected to Meet Conditions for Revising Conversion Price
- Announcement on Repurchasing and Canceling Restricted Stocks Granted to Some Incentive Objects But Not Yet Lifted from Sales Restrictions
- Announcement on 2026 Interest Payment of "East-Asia Convertible Bonds"
- Announcement on SSE’s Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
Later from Zhejiang East Asia Pharmaceutical
- Announcement on Implementation of Repurchase and Cancellation of Certain Restricted Shares under the Equity Incentive Plan
- Semi-annual Report for 2026
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Abnormal Fluctuations in Stock Trading
- (605177)"Zhejiang East-Asia Pharmaceutical Co., Ltd."Announcement on Conversion Results of Convertible Bonds and Share Changes
Follow Zhejiang East Asia Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang East Asia Pharmaceutical